Gayatri Saberwal

Biographic Data

ID9065142
NAMEGayatri Saberwal
GIVEN NAMESGayatri
FAMILY NAMESaberwal
SIGNATURESABERWAL G
AFFILIATIONSInstitute of Bioinformatics and Applied Biotechnology
ORCID0000-0003-2410-1431
VERIFIEDYes
TOTAL WORKS4
TOTAL CITATIONS0
WORKS AS AUTHOR4
WORKS AS EDITOR0
FIRST PUBLICATION YEAR2022
LATEST PUBLICATION YEAR2022
H-INDEX0

  • Are Countries Becoming Better at Sars-CoV-2 Genomic Surveillance

    Open AccessUtkarsha Mahanta, Gayatri Saberwal et al.ARTICLEFrontiers in Public Health2022

    OPINION article Front. Public Health, 25 April 2022Sec. Public Health Policy https://doi.org/10.3389/fpubh.2022.887955

  • An analysis of deficiencies in the ethics committee data of certain interventional trials registered with the Clinical Trials Registry–India

    Open AccessIndraneel Chakraborty, Adya Shreya et al.ARTICLEPLOS Global Public Health2022

    There is widespread agreement that clinical trials should be registered in a public registry, preferably before the trial commences. It is also important that details of each trial in the public record are complete and accurate. In this study, we examined the trial sites and ethics committee (EC) data for 1359 recent Phase 2 or Phase 3 interventional trials registered with Clinical Trials Registry–India (CTRI), to identify categories of problems …

  • Rare disease patients in India are rarely involved in international orphan drug trials

    Open AccessMonoswi Chakraborty, Mohua Chakraborty Choudhury et al.ARTICLEPLOS Global Public Health2022

    We wished to determine whether rare diseases patients from India had been enrolled in international trials to develop novel orphan drugs. There are two reasons to be interested in this. (a) Different ethnic or racial groups may respond differently to a particular drug. India has huge ethnic diversity, and to exclude such participants is to severely limit the diversity of any trial; (b) Even if a suitable drug for a rare disease is available in In…

  • Discrepancies between FDA documents and ClinicalTrials.gov for Orphan Drug-related clinical trial data

    Open AccessMohua Chakraborty Choudhury, Indraneel Chakraborty et al.ARTICLEPLOS Global Public Health2022

    Clinical trial registries such as ClinicalTrials.gov (CTG) hold large amounts of data regarding trials. Drugs for rare diseases are known as orphan drugs (ODs), and it is particularly important that trials for ODs are registered, and the data in the trial record are accurate. However, there may be discrepancies between trial-related data that were the basis for the approval of a drug, as available from Food and Drug Administration (FDA) documents…